Infusion Pumps Segment to Lead North America Infusion Devices Market During 2023-2031

According to our new research study on "North America Infusion Devices Market Forecast to 2031 - Regional Analysis - by Product Type, Application, and End User," the market size is projected to reach US$ 9,116.47 million by 2031 from US$ 5,494.15 million in 2023. The market is expected to register a CAGR of 6.5% during 2023-2031.The market report emphasizes trends prevalent in the market, along with drivers and deterrents affecting its growth. Owing to the increasing prevalence of cancer and the rising geriatric populations, infusion devices with intelligent features such as easy integration, remote monitoring, and electronic record-keeping are likely to remain key trends in the market in the coming years.

The US holds the largest North America infusion devices market share and is estimated to dominate the market during the forecast period. The US market growth is attributed to the rising chronic disease prevalence and the increasing geriatric population in the US. The unprecedented rate of an aging population and extended periods of physical inactivity boost the prevalence of lifestyle disorders such as cardiovascular disease (CVDs), diabetes, obesity, and others. According to the Diabetes Research Institute, the number of people affected by diabetes in the US was ~37.3 million (i.e., 11.3% of the population) in 2022. Nearly 28.7 million people in the country were diagnosed with diabetes, and ~8.6 million people have undiagnosed diabetes. Further, ~1.4 million diabetes cases are diagnosed each year in the US. According to Yale researchers, in 2022, ~30 million people in the country had diabetes, and about 7 million require daily insulin. An insulin pump is a small device that can continuously deliver insulin to manage carbohydrate intake. The pump contains a reservoir connected to a small plastic tube, called a cannula, through which insulin is infused into fatty tissue. The cannula, along with a needle called an infusion set, is inserted under the skin for insulin delivery.

The rising number of product approvals from the US Food and Drug Administration (FDA) and the presence of market players in the country boost the US infusion devices market growth. Below mentioned are a few instances:

• In May 2024, Moog Inc. received 510(k) clearance for the Industrial segment's CURLIN 8000 Ambulatory Infusion System. The premium infusion platform was specifically developed for use in home infusion settings.
• In August 2023, ICU Medical, Inc. announced that the company received FDA 510(k) regulatory clearance for the Plum Duo infusion pump with LifeShield infusion safety software. The Plum Duo pump and LifeShield software will be available to customers in the US in early 2024.
• In July 2023, BD announced that the updated BD Alaris Infusion System received 510(k) clearance, which enables remediation and a return to full commercial operations for the most comprehensive infusion system available in the US.
• In August 2022, Baxter International Inc. announced the FDA clearance of its new Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software. It represents Baxter's latest development for infusion therapy. The Novum IQ SYR can seamlessly integrate with hospital electronic medical records (EMRs) through Baxter's IQ Enterprise Connectivity Suite.

Thus, the rising prevalence of diabetes and increasing number of FDA approvals drive the demand of infusion devices in the US.

Based on product type, the North America infusion devices market is bifurcated into infusion pumps and infusion sets. The infusion pumps segment held a larger market share in 2023, and it is expected to register a higher CAGR in the market during 2023-2031. Volumetric pumps, syringe pumps, elastomeric pumps, insulin pumps, enteral pumps, patient control analgesia pumps are a few types of infusion pumps. Growing cases of chronic diseases such as cancer, diabetes, and others propel the requirement for the treatment of these diseases, which enhances the demand for different types of infusion pumps as per the disease application.

Market players are launching products with advanced technologies for various disease applications. For instance, In April 2024, Baxter International Inc. announced the clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. This addition of LVP modality to the Novum IQ Infusion Platform-which includes Baxter's syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite-allows clinicians to use a single, integrated system across various patient care settings. The introduction of Novum IQ LVP in the US demonstrates Baxter's dedication to ongoing innovation in advancing infusion therapy.

• By application, the market is segmented into diabetes, oncology, pain management, hematology, pediatrics, gastroenterology, and others. The diabetes segment held the largest share of the market in 2023, and it is projected to register the highest CAGR in the market during 2023-2031.
• Based on end user, the North America infusion devices market is divided into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2023. The homecare settings segment is anticipated to register the highest CAGR during 2023-2031.

Becton Dickinson and Co, Fresenius Kabi AG, B Braun SE, CODAN US Corp, Baxter International Inc., Elimedical Inc., ICU Medical Inc., BPL Medical Technologies Pvt Ltd, Nipro Corp., KD Scientific Inc., Medtronic Plc, Zimed Healthcare Ltd, Terumo Corp., Eitan Medical Ltd, Polymedicure, and Moog Inc. are among the leading companies profiled in the North America infusion devices market report.

As per the company news, few of the developments in the market are as follows:

• In April 2024, Mackenzie Health launched a technology in Canada that allows for two-way information flow between an intravenous (IV) medication pump and a patient's electronic medical record. The technology, known as BD Alaris EMR Interoperability, eliminates the need for healthcare professionals to manually program pumps. It sends infusion safety information back to Epic EMR, reducing the risk of administration errors and providing an accurate infusion record in the EMR.
• In November 2022, Medtronic plc announced the launch of Medtronic Extended infusion set in the US. It is the first and only infusion set labeled for up to seven-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and usually needs to be changed every 2-3 days.
• In May 2022, Fresenius Kabi acquired Ivenix, along with its advanced infusion pump technology, expanding its portfolio of advanced infusion pumps and solutions for healthcare professionals to address healthcare needs across the care continuum. This acquisition allowed Fresenius Kabi to rapidly expand its infusion therapy portfolio in the US, obtaining FDA approvals for multiple IV solutions in anticipation of qualifying its North Carolina manufacturing site to supply US customers with IV solutions.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com